Researchers and a specialty pharmaceutical company have taken a longstanding theory about addiction and have used it to develop a novel approach to its treatment with medication, in the hope of creating the breakthrough drug for patients with cocaine dependence.
Robert Linke, Embera’s president and CEO, spoke with CEOCFO Magazine regarding Embera’s new approach to treating addictions and how attitudes toward addiction are evolving.
Robert Linke, president and CEO of Embera Neurotherapeutics, a specialized biopharmaceutical firm based in Shreveport, Louisiana spoke with Drug Discovery & Development via email about his company’s progress on the development of drugs that battle addiction.
Listen to the 2/18/14 episode of BioTech Nation with host Dr. Moira Gunn. Robert Linke, Embera’s CEO, discusses EMB-001 and smoking cessation.
Addictive behaviors – from tobacco use to eating disorders – are among the most difficult to treat and the least likely to result in permanent recovery. That’s precisely why Embera NeuroTherapeutics Inc. is excited about prospects for its EMB-001 . Rather than seeking to block the effects of an addictive substance or substitute a safer compound, the firm’s drug combination suppresses the craving that drives addiction.